Mechanism of KRAS G12C Inhibition in Non-Small Cell Lung Cancer
Small-molecule inhibitors covalently lock KRAS(G12C) in its inactive GDP-bound state, selectively halting downstream MAPK signaling cascades [Canon et al., Nature 2019]. Subsequent phase III clinical trials established significant progression-free survival benefits over standard docetaxel chemotherapy [Jänne et al., NEJM 2022].
"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity."
DOI: 10.1038/s41586-019-1694-1 • Cited: 1,842xZero Hallucination
Every single claim is mapped directly to indexed scientific DOI passages with verifiable evidence pages.
2,000+ Citation Styles
Switch between APA 7th, IEEE, Nature, Harvard, Chicago, or Vancouver with one single click.
Mathematical Rigor
Full support for native LaTeX equations, chemical formulas, and statistical notation without rendering artifacts.
Academic Tone Control
Adjust tone between Grant Proposal, Peer-Reviewed Manuscript, Review Article, or Dissertation Chapter.